酒石酸美托洛尔联合稳心颗粒治疗冠心病早搏的疗效

Therapeutic efficacy of Metoprolol tartrate joint with Wenxinkel on premature coronary heart disease

目的:探讨酒石酸美托洛尔联合稳心颗粒在冠心病早搏治疗中的临床疗效。方法:收治冠心病早搏患者78例,随机将上述患者分为对照组和观察组,每组39例。对照组单纯使用酒石酸美托洛尔进行治疗,观察组在此基础上联用稳心颗粒治疗,比较两组的疗效及临床症状的改善情况。结果:对照组总有效率64.10%,观察组总有效率94.87%。因早搏所致的心悸、胸闷、气短等症状改善明显,两组的治疗总有效率和症状改善情况均差异显著,具有统计学意义(P<0.05)。结论:联用酒石酸美托洛尔和稳心颗粒治疗冠心病早搏疗效显著,可有效改善因早搏所致的各种临床症状,同时安全性较高。

Objective:To investigate the clinical efficacy of metoprolol tartrate Wenxinkeli in the treatment of premature coronary heart disease.Premature coronary heart disease.Methods:From June 2012 to June 2013,78 cases of patients with premature coronary heart disease was admitted to the study,were randomly divided into control group and observation group,39 cases in each group.The control group were treated with metoprolol tartrate,based on the above treatment,the observation group was treated with Wenxinkeli treatment,compare the premature and improvement of clinical symptoms bettwen two groups.Results:The total efficiency of premature in the control group was 64.10%,and the observation group was 94.87%.Palpitations,chest tightness, shortness of breath,etc caused by premature improved significantly,overall efficiency and improvement of symptoms were significantly different in two groups,and statistically significant(P<0.05).Conclusion:Metoprolol tartrate combined with Wenxinkeli treat coronary heart disease and premature have a significant effect,and effectively improve the variety of clinical symptoms caused by premature,and high security,worthy of learning and promotion.